RENB: Renovaro Inc. Stock

by  •  • Comments Off on RENB: Renovaro Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 121.16
Enterprise Value ($M) 123.65
Book Value ($M) 98.09
Book Value / Share 0.62
Price / Book 1.24
NCAV ($M) -21.80
NCAV / Share -0.14
Price / NCAV -5.56

Profitability (mra)
Return on Invested Capital (ROIC) -1.13
Return on Assets (ROA) -1.99
Return on Equity (ROE) -2.65

Liquidity (mrq)
Quick Ratio 0.08
Current Ratio 0.08

Balance Sheet (mrq) ($M)
Current Assets 1.95
Assets 121.83
Liabilities 23.75
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -27.39
Net Income -80.65
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -10.97
Cash from Investing -1.26
Cash from Financing 10.52

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-06 13D/A William Anderson Wittekind 11.40 0.00
02-22 13G/A Abildgaard Ole 7.60 9.84
02-16 13D/A Sindlev Rene 10.28 35.49

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-10-28 10-K/A United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION report under sec
2024-10-10 10-K United states SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL report under section 13 Or 15(d) of the securities exchange act of 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION report under section 13 Or 15(d) o
2024-08-20 10-Q/A U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-05-15 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 1
2024-02-14 10-Q U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTIO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 175,718 506,557 34.69
2025-02-03 84,284 256,238 32.89
2025-01-31 55,636 199,251 27.92
2025-01-30 184,892 380,187 48.63

(click for more detail)

Similar Companies
PTPI – Petros Pharmaceuticals, Inc. PULM – Pulmatrix, Inc.
QLGN – Qualigen Therapeutics, Inc. REVB – Revelation Biosciences, Inc.
RGC – Regencell Bioscience Holdings Limited


Financial data and stock pages provided by
Fintel.io